An observational study in Psoriatic Arthritis (PsA) and Subclinical Right Ventricular Systolic Dysfunction, sponsored by Ain Shams University. Not yet recruiting at 1 site in Egypt. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Ain Shams University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Psoriatic with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Arthritis, Psoriatic · Egypt.
Among the 10 studies in Arthritis, Psoriatic with a site in Egypt, this one is one of 3 that started in 2025, is one of 4 observational ones, and was the 6th registered.
602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →6 of the 10 studies in Arthritis, Psoriatic with a site in Egypt are open now. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
South Valley University · Sites in Egypt
Ages 18–50
Tanta University · Sites in Egypt
Ages 18–70
Egymedicalpedia · Sites in Egypt
Ages 20–40 · Women only · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 20 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 280 across 244 observational studies indexed under Arthritis, Psoriatic.
Median enrollment 53 across the 6 interventional studies, 143 across the 4 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 6 most frequent:
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Ain Shams University has 1 study filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Psoriatic with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07398651Tanta UniversityApremilast and Adalimumab in Psoriatic Arthritis Patients | 2026-12-30 |
| NCT07046312Ain Shams UniversityRight Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level | 2027-04 |
| NCT07946497South Valley UniversityCAPN12 Gene Expression as a Molecular Discriminator | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Arthritis, Psoriatic with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain echocardiography
Previous studies evaluated RV strain for detection of subclinical RV affection due to PAH in systemic lupus erythematosus. However , to our knowledge , the study of RV strain and its possible association with serum endostatin to detect subclinical right ventricular systolic dysfunction and its relation to PAH in PsA patient is still a novel. Our aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain Echocardiography.
To evaluate serum endostatin as an objective biomarker for Pulmonary arterial hypertension.
30 patients with PsA and 30 matched healthy controls
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 control group matched as regards BMI, age and sex will be subjected to transthoracic echo and measuring serum endostatin level.
30 PsA patients will be subjected to transthoracic echo, measuring serum endostatin level and modified composite psoriatic disease activity index
Detecting subclinical right ventricular systolic dysfunction in PsA patients
Detecting subclinical right ventricular systolic dysfunction in PsA using 2D strain transthoracic echo and its relation to serum endostatin level
Time frame: Up to 24 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jul 2025; primary completion for Apr 2027, 21 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.